Susquehanna International Group
FENC icon

Susquehanna International Group’s Fennec Pharmaceuticals FENC Stock Holding History

Susquehanna International Group’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,200
Closed -$91.6K – 12623
2023
Q3 		$91.6K Sell
12,200
-12,900
-51% -$105K ﹤0.01% 10994
2023
Q2 		$222K Sell
25,100
-8,500
-25% -$70.7K ﹤0.01% 10066
2023
Q1 		$280K Buy
33,600
+14,000
+71% +$130K ﹤0.01% 9872
2022
Q4 		$188K Sell
19,600
-49,700
-72% -$440K ﹤0.01% 10223
2022
Q3 		$561K Sell
69,300
-51,200
-42% -$351K ﹤0.01% 8183
2022
Q2 		$681K Buy
120,500
+106,500
+761% +$618K ﹤0.01% 7486
2022
Q1 		$78K Sell
14,000
-19,600
-58% -$98.8K ﹤0.01% 12068
2021
Q4 		$148K Buy
33,600
+12,500
+59% +$93K ﹤0.01% 11806
2021
Q3 		$199K Buy
+21,100
New +$158K ﹤0.01% 11485
2020
Q4 		– Sell
-10,700
Closed -$65K – 11201
2020
Q3 		$65K Sell
10,700
-9,800
-48% -$69.1K ﹤0.01% 10118
2020
Q2 		$171K Buy
+20,500
New +$152K ﹤0.01% 9161

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Susquehanna International Group's FENC Position: Q4 2025 in Review

Susquehanna International Group sold out of Fennec Pharmaceuticals (FENC) in Q4 2025, closing a stake of 17,023 shares — an estimated $159K sold.

Susquehanna International Group first reported a position in FENC in Q1 2018 and held it in 21 quarters. The position peaked at $1.34M in Q1 2023. 96 funds tracked by Wall St. Rank hold FENC as of Q4 2025.

  • Susquehanna International Group reported no remaining Fennec Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 17,023 Fennec Pharmaceuticals shares in Q4 2025, an estimated $159K.
  • Susquehanna International Group first reported a position in Fennec Pharmaceuticals in Q1 2018 and held it in 21 quarters.
  • Susquehanna International Group's Fennec Pharmaceuticals position peaked at $1.34M in Q1 2023.
  • 96 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.